Formycon AG (XTER:FYB)
€ 18.16 -0.10 (-0.55%) Market Cap: 320.94 Mil Enterprise Value: 261.65 Mil PE Ratio: 0 PB Ratio: 0.83 GF Score: 64/100

Q1 2026 Formycon AG Earnings Call Transcript

May 28, 2026 / 01:00 PM GMT
Release Date Price: €21.3 (+5.19%)

Key Points

Positve
  • Formycon AG (WBO:FYB) reported significant revenue growth in Q1 2026, more than doubling compared to Q1 2025.
  • The company successfully launched its third pipeline product, FIB203, a biosimilar to EYLEA, in Europe.
  • Formycon AG achieved multiple key milestones across its FIP for growth strategy, including positive results from FIP206.
  • The company is expanding its global footprint through strategic partnerships, enhancing its commercial platform.
  • Formycon AG's EBITDA improved significantly by more than $11 million compared to Q1 2025, indicating strong financial performance.
Negative
  • The adjusted EBITDA for Q1 2026 was negative, reflecting a negative contribution from the joint venture BioAC AG.
  • R&D expenses have been reduced, but the company still faces challenges with cost management in early-stage developments.
  • The company relies on deferred milestones for revenue recognition, which may lead to volatility if milestones are not achieved.
  • Formycon AG's cash and cash equivalents reduced to $54 million at the end of Q1 2026, indicating cash flow challenges.
  • There is uncertainty regarding the launch timeline for FIP206 in the US and Europe, which could impact future revenue.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

FYB.DE - Formycon AG
Q1 2026 Formycon AG Earnings Call
May 28, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, ladies and gentlemen, and welcome to the Formicron AG Earnings Call Q1 2026. At this time, all participants have been placed on a listening-only mode. The floor will be open for questions following the presentation within the conference call. Let me now turn the floor over to your host, Dr. Stefan from Weitzer.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Yes, thank you and good afternoon, good morning and welcome to everyone joining us today.

Earlier today, we published our Q1 results for 2026. And before we move to the presentation, let me highlight just some key
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot